Compare Amgen, Inc. (AMGN) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nutanix Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Nutanix Inc trades at $54.79 (market cap $14.81B). The key difference: Amgen, Inc. is far larger — about 13.2× Nutanix Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| AMGN | NTNX | |
|---|---|---|
Market Cap | $196.12B | $14.81B |
Sector | Health | Technology |
52-Week High | $388.16 | $81.12 |
52-Week Low | $271.18 | $34.41 |
Enterprise Value | $241.41B | $14.32B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Nutanix (NTNX) trades at $54.79, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals, with Q1 2026 EPS of $0.47 beating expectations and a robust gross profit margin of 87.09%. Recent news highlights momentum, including NVIDIA certification for its storage solution and positive analyst coverage.
The outlook is positive, driven by consistent earnings beats, expanding AI infrastructure opportunities, and a consensus price target of $57.80. Key risks include high valuation multiples and competitive pressures in the hybrid cloud market. Wall Street sentiment is bullish, with 62.5% of analysts rating the stock a Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
